Scholar Rock Holding Croissance future

Future contrôle des critères 2/6

Scholar Rock Holding devrait augmenter ses bénéfices et son chiffre d'affaires de 53.4% et de 68.4% par an respectivement. Le BPA devrait croître de de 56.9% par an. Le rendement des capitaux propres devrait être -23.1% dans 3 ans.

Informations clés

53.4%

Taux de croissance des bénéfices

56.9%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.3%
Taux de croissance des recettes	68.4%
Rendement futur des capitaux propres	-23.1%
Couverture par les analystes	Good
Dernière mise à jour	26 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Scholar Rock Holding Corporation's (NASDAQ:SRRK) Share Price Not Quite Adding Up

Apr 19

Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy

Oct 20

Jay Backstrom is the new CEO at Scholar Rock

Sep 20

Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology

Jul 12

Brokers Are Upgrading Their Views On Scholar Rock Holding Corporation (NASDAQ:SRRK) With These New Forecasts

May 21

Broker Revenue Forecasts For Scholar Rock Holding Corporation (NASDAQ:SRRK) Are Surging Higher

Mar 08

Scholar Rock Holding Corporation (NASDAQ:SRRK) Analysts Are More Bearish Than They Used To Be

May 15

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:SRRK - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	184	-114	-125	-74	8
12/31/2025	26	-244	-206	-229	9
12/31/2024	N/A	-243	-155	-200	9
9/30/2024	N/A	-226	-189	-189	N/A
6/30/2024	N/A	-204	-169	-169	N/A
3/31/2024	N/A	-183	-152	-152	N/A
12/31/2023	N/A	-166	-145	-145	N/A
9/30/2023	N/A	-159	-137	-137	N/A
6/30/2023	N/A	-160	-131	-131	N/A
3/31/2023	N/A	-166	-134	-133	N/A
12/31/2022	33	-135	-134	-133	N/A
9/30/2022	37	-131	-138	-136	N/A
6/30/2022	43	-125	-149	-146	N/A
3/31/2022	47	-112	-146	-143	N/A
12/31/2021	19	-132	-132	-127	N/A
9/30/2021	18	-122	-121	-114	N/A
6/30/2021	16	-109	-109	-101	N/A
3/31/2021	15	-97	-96	-89	N/A
12/31/2020	15	-86	-64	-60	N/A
9/30/2020	20	-71	-60	-57	N/A
6/30/2020	21	-64	-50	-48	N/A
3/31/2020	22	-57	-48	-45	N/A
12/31/2019	20	-51	-66	-63	N/A
9/30/2019	13	-54	6	8	N/A
6/30/2019	8	-49	12	14	N/A
3/31/2019	3	-51	17	19	N/A
12/31/2018	N/A	-49	23	25	N/A
9/30/2018	N/A	-43	-37	-37	N/A
6/30/2018	N/A	-38	N/A	-33	N/A
3/31/2018	N/A	-29	N/A	-27	N/A
12/31/2017	N/A	-25	N/A	-22	N/A
12/31/2016	0	-16	N/A	-15	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: SRRK devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: SRRK devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: SRRK devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de SRRK ( 68.4% par an) devrait croître plus rapidement que le marché US ( 8.9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de SRRK ( 68.4% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: SRRK devrait être non rentable dans 3 ans.

Scholar Rock Holding Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Price target increased by 15% to US$42.88

Price target increased by 11% to US$29.75

Price target increased by 8.1% to US$26.25

Price target increased by 7.1% to US$25.71

Price target increased by 9.8% to US$24.00

Price target decreased to US$22.57

Recent updates

Price target increased by 15% to US$42.88

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million.

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million.

Scholar Rock Holding Corporation has filed a Follow-on Equity Offering in the amount of $275 million.

Price target increased by 11% to US$29.75

Scholar Rock: SMA Program Strides Forward With Positive Clinical Data

Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 Sapphire Study in Patients with Spinal Muscular Atrophy

Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

Health Check: How Prudently Does Scholar Rock Holding (NASDAQ:SRRK) Use Debt?

New major risk - Financial position

Scholar Rock Holding Corporation Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal

CFO, COO & Treasurer recently sold US$85k worth of stock

Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Scholar Rock Holding Corporation, Annual General Meeting, Jun 27, 2024

New major risk - Shareholder dilution

Health Check: How Prudently Does Scholar Rock Holding (NASDAQ:SRRK) Use Debt?

Price target increased by 8.1% to US$26.25

New minor risk - Share price stability

New major risk - Financial position

President recently sold US$183k worth of stock

Scholar Rock Announces Management Appointments

Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management

Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity

Scholar Rock: Solid Data And Good Prospects

CFO, COO & Treasurer notifies of intention to sell stock

Senior VP & Head of Research recently sold US$295k worth of stock

CFO, COO & Treasurer notifies of intention to sell stock

Price target increased by 7.1% to US$25.71

New major risk - Revenue and earnings growth

CFO, COO & Treasurer notifies of intention to sell stock

Scholar Rock, Inc. Presents New Data from Phase 1 Dragon Trial Showing Promising Anti-Tumor Activity in Anti-Pd-1 Resistant Metastaticcc Patients and Supporting Srk-181 Continued Tolerability

Price target increased by 9.8% to US$24.00

Scholar Rock Announces to Present Clinical and Biomarker Data from the Phase 1 Dragon Trial At the Sitc 38Th Annual Meeting

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.

Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial

Scholar Rock Announces New Data from the Phase 2 TOPAZ Trial Extension Period Evaluating Patient Outcomes At 36 Months of Treatment with Apitegromab

Scholar Rock Holding Corporation, Annual General Meeting, Jun 21, 2023

Scholar Rock Holding Corporation's (NASDAQ:SRRK) Share Price Not Quite Adding Up

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer

Price target decreased to US$22.57

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.02 loss in 3Q 2021)

Scholar Rock Holding Corporationa Announces Recent Phase 1 Dragon Data Show Srk-181 Continues to Be Well Tolerated with Early Indications of Efficacy

Scholar Rock Appoints Jing L. Marantz as Chief Medical Officer

Scholar Rock Holding Corporation Announces New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA

Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy

Scholar Rock Announces Chief Executive Officer Changes

Jay Backstrom is the new CEO at Scholar Rock

Second quarter 2022 earnings released: US$1.06 loss per share (vs US$0.84 loss in 2Q 2021)

Scholar Rock Holding Corporation Appoints Srinivas Akkaraju to Board of Directors

Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology

Scholar Rock Holding Corporation(NasdaqGS:SRRK) dropped from Russell 2000 Growth Index

Price target decreased to US$29.00

Scholar Rock Announces New Data from the Phase 2 Topaz Trial Extension Period Evaluating Patient Outcomes After 24-Months of Treatment

Consensus revenue estimates increase by 75%

Consensus revenue estimates increase by 75%

Brokers Are Upgrading Their Views On Scholar Rock Holding Corporation (NASDAQ:SRRK) With These New Forecasts

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Scholar Rock Holding Corporation Provides Pipeline Updates

Price target decreased to US$44.67

Price target decreased to US$46.17

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

Broker Revenue Forecasts For Scholar Rock Holding Corporation (NASDAQ:SRRK) Are Surging Higher

Scholar Rock Holding Corporation Provides Corporate Update and Highlights Priorities for 2022

Price target decreased to US$55.80

Scholar Rock Holding Corporation Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA)

CFO & Head of Business Operations exercised options and sold US$2.8m worth of stock